Released Nov 21, 2011, after the close
10-Q filed Nov 21, 2011, 52 days after period end · 0001193805-11-002241
Q3 2011 · 10-Q
Revenue$6.25M$6.25M +9.6% vs Q3 2010+25.2% vs Q2 2011
Net Income-$1.45M-$1.45M N/M vs Q3 2010N/M vs Q2 2011
EPS Diluted-$0.11-$0.11 N/M vs Q3 2010N/M vs Q2 2011
Gross Profit$2,243,621+6.6%
Operating Income$1,203,796−3.4%
Operating Cash Flowderived$25,917−97.5%
Free Cash Flowderived-$350,540N/M
Margins · derived
Gross margin35.9%−1.0 pt vs Q3 2010
Operating margin19.3%−2.6 pt vs Q3 2010
Net margin-23.1%−36.5 pt vs Q3 2010
What the release said
No earnings release is on file for this quarter. Its figures came with the 10-Q.
Same quarter
| Metric | Q3 2011 | Q3 2010 |
|---|---|---|
| Revenue | $6.25M | $5.70M |
| Net Income | -$1.45M | $760.16K |
| EPS Diluted | -$0.11 | $0.10 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Tanke Biosciences Corp · CIK 1452011 · Engraved from SEC EDGAR